What is Erlotinib?

Category: Prescription Drugs

Most popular types: Tarceva

false

Erlotinib is an orally administered medication that can be used to treat locally advanced or metastatic EGFR positive non-small cell lung cancer (NSCLC). It can also be used in combination with gemcitabine as a first-line treatment for locally advanced, unresectable, or metastatic pancreatic cancer.

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Adenocarcinoma (non-small cell lung cancer) 33 22
Lung cancer 4 3
Non-small cell lung cancer 4 2
Small cell lung cancer 1 1
Unclassified carcinoma (non-small cell lung cancer) 1 1

  • Major
  • Moderate
  • Slight
  • None
  • Can't tell

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 6
Moderate 10
Mild 12
None 1

Commonly reported side effects and conditions associated with Erlotinib

Side effect Patients Percentage
Diarrhea 13
Dry skin 4
Rashes (redness, swelling) 4
Fatigue 3
Rash on face 3
Acne breakout 2

Show all 31 reported side effects

Why patients stopped taking Erlotinib

Multiple reasons could be selected

Reason Patients Percentage
Did not seem to work 3
Side effects too severe 3
Doctor's advice 2
Other 2
Personal research 1
See all 10 patients who've stopped taking Erlotinib

Duration

Stopped taking Erlotinib

Duration Patients Percentage
1 - 6 months 1
6 months - 1 year 3
1 - 2 years 4
2 - 5 years 1
10 years or more 1
Adherence
Adherence Evaluations Percentage
Always 26
Usually 0
Sometimes 2
Never taken as prescribed 1
Burden
Burden Evaluations Percentage
Very hard to take 0
Somewhat hard to take 1
A little hard to take 10
Not at all hard to take 18
Cost per month
Cost per month Evaluations Percentage
$200+ 1
$100-199 3
$50-99 2
$25-49 3
< $25 6
Not specified 14

What people switch to and from

Patients started taking Erlotinib after stopping:

Treatment Patients Percentage
Chemotherapy 1
Gefitinib (Iressa) 1

Patients stopped taking Erlotinib and switched to:

Treatment Patients Percentage
Osimertinib (Tagrisso) 5
Gefitinib (Iressa) 2
Afatinib (Gilotrif) 1
Chemotherapy 1
Pembrolizumab (Keytruda) 1
Last updated:
There are no evaluations for Erlotinib.